A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply

N Engl J Med. 2024 May 2;390(17):1632-1633. doi: 10.1056/NEJMc2402905.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Clinical Trials, Phase III as Topic
  • Fatty Liver / complications
  • Fatty Liver / drug therapy
  • Humans
  • Liver Cirrhosis* / drug therapy
  • Liver Cirrhosis* / etiology
  • Non-alcoholic Fatty Liver Disease* / complications
  • Non-alcoholic Fatty Liver Disease* / drug therapy
  • Pyridazines* / therapeutic use
  • Thyroid Hormone Receptors beta / agonists
  • Uracil / analogs & derivatives

Substances

  • Pyridazines
  • resmetirom
  • Thyroid Hormone Receptors beta
  • Uracil